Evidence map›Paper›PMID 27419662›Full record

ArticlePopulation health management2017

Treatment and Survival of Medicare Beneficiaries with Colorectal Cancer: A Comparative Analysis Between a Rural State Cancer Registry and National Data.

Pallavi B Rane, S Suresh Madhavan, Usha Sambamoorthi, Kalidindi Sita, Sobha Kurian, Xiaoyun Pan

Abstract readComparative Study
In one paragraph

Article in Population health management, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Pallavi B Rane1 Center for the Evaluation of Value and Risk in Health, Tufts Medical Center Institute for Clinical Research and Health Policy Studies , Boston, MA.
S Suresh Madhavan2 Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University , Morgantown, WV.
Usha Sambamoorthi2 Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University , Morgantown, WV.
Kalidindi Sita2 Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University , Morgantown, WV.
Sobha Kurian3 Department of Radiology Hematology/Oncology, Mary Babb Randolph Cancer Center, West Virginia University , Morgantown, WV.
Xiaoyun Pan4 Evidera, Lexington, MA.

Funding

West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Sally Lynn Hodder · 2012 to 2026
$81.0M
AHRQ HHS R24 HS018622NIGMS NIH HHS U54 GM104942
6 · The paper itself

Abstract

The aim was to examine and compare with "national" estimates, receipt of colorectal cancer (CRC) treatment in the initial phase of care and survival following a CRC diagnosis in rural Medicare beneficiaries. A retrospective study was conducted on fee-for-service Medicare beneficiaries diagnosed with CRC in 2003-2006, identified from West Virginia Cancer Registry (WVCR)-Medicare linked database (N = 2119). A comparative cohort was identified from Surveillance, Epidemiology, and End Results (SEER)-Medicare (N = 38,168). CRC treatment received was ascertained from beneficiaries' Medicare claims in the 12 months post CRC diagnosis or until death, whichever happened first. Receipt of minimally appropriate CRC treatment (MACT) was defined using recommended CRC treatment guidelines. All-cause and CRC-specific mortality in the 36-month period post CRC diagnosis were examined. Differences in usage of CRC surgery, chemotherapy, and radiation were observed between the 2 populations, with those from WVCR-Medicare being less likely to receive any type of CRC surgery (adjusted odds ratio [AOR] = 0.82; 95% confidence interval [CI] = [0.73-0.93]). Overall, those from WVCR-Medicare had a lower likelihood of receiving MACT, (AOR = 0.85; 95% CI = [0.76-0.96]) compared to their national counterparts. Higher hazard of CRC mortality was observed in the WVCR-Medicare cohort (adjusted hazard ratio = 1.26; 95% CI = [1.20-1.32]) compared to the SEER-Medicare cohort. Although more beneficiaries from WVCR-Medicare were diagnosed in early-stage CRC compared to their SEER-Medicare counterparts, they had a lower likelihood of receiving MACT and a higher hazard of CRC mortality. This study highlights the need for an increased focus on improving access to care at every phase of the CRC care continuum, especially for those from rural settings.

Indexed as

MedicareRegistriesRural PopulationAgedAged, 80 and overColorectal NeoplasmsDatabases, FactualFemaleHumansMaleProportional Hazards ModelsRetrospective StudiesSEER ProgramSurvival AnalysisUnited StatesWest Virginia

Identifiers

PMID27419662
PMCPMC5278801

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.